Genmab | GEN - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Almirall EUR 214.79M 0 2025-12
Amarin USD 20.81M 13K 2025-12
Amgen USD 541M 1000K 2026-06
argenx SE USD 62.54M 2.74M 2026-06
AstraZeneca USD 1.55B 44K 2026-06
Bayer EUR 982.42M 0 2026-03
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Demant DKK 210.9M 5.18M 2025-12
Exelixis USD 253.7M 8.78M 2026-03
Fresenius Medical Care EUR 270.09M 9.2M 2026-03
Genmab DKK 61.62M 52K 2025-12
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
GN Store Nord DKK 145.61M 0 2026-03
GRIFOLS EUR 680.58M 6K 2026-06
Hikma Pharmaceutical USD 221.89M 181.89M 2025-12
Insmed USD 216.52M 2.27M 2026-03
Lakefront Biotherapeutics EUR 65.9M 0 2026-03
Lonza CHF 68.64M 0 2025-12
Merck EUR 434.78M 0 2026-03
Novartis USD 1.9B 7.38M 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.21B 8.25M 2026-03
UCB EUR 190.36M 365.15K 2025-12